- Home
- BDRX vs LGVN Comparison
BDRX vs LGVN Comparison
Compare BDRX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- LGVN
- Stock Information
- Founded
- BDRX 2000
- LGVN 2014
- Country
- BDRX United Kingdom
- LGVN United States
- Employees
- BDRX N/A
- LGVN N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BDRX Health Care
- LGVN Health Care
- Exchange
- BDRX Nasdaq
- LGVN Nasdaq
- Market Cap
- BDRX 5.8M
- LGVN 23.4M
- IPO Year
- BDRX N/A
- LGVN 2021
- Fundamental
- Price
- BDRX $0.87
- LGVN $1.29
- Analyst Decision
- BDRX
- LGVN Strong Buy
- Analyst Count
- BDRX 0
- LGVN 3
- Target Price
- BDRX N/A
- LGVN $8.67
- AVG Volume (30 Days)
- BDRX 3.1M
- LGVN 134.1K
- Earning Date
- BDRX 04-11-2025
- LGVN 08-13-2025
- Dividend Yield
- BDRX N/A
- LGVN N/A
- EPS Growth
- BDRX N/A
- LGVN N/A
- EPS
- BDRX N/A
- LGVN N/A
- Revenue
- BDRX N/A
- LGVN $2,225,000.00
- Revenue This Year
- BDRX N/A
- LGVN N/A
- Revenue Next Year
- BDRX N/A
- LGVN $51.48
- P/E Ratio
- BDRX N/A
- LGVN N/A
- Revenue Growth
- BDRX N/A
- LGVN 127.50
- 52 Week Low
- BDRX $0.78
- LGVN $1.14
- 52 Week High
- BDRX $41.50
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- BDRX 37.11
- LGVN 49.31
- Support Level
- BDRX $0.83
- LGVN $1.27
- Resistance Level
- BDRX $0.90
- LGVN $1.40
- Average True Range (ATR)
- BDRX 0.10
- LGVN 0.08
- MACD
- BDRX 0.01
- LGVN 0.01
- Stochastic Oscillator
- BDRX 15.94
- LGVN 56.00
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.